Photograph of Adam Heckman

Adam Heckman Partner Lawyer and Patent Agent

Parle :  Anglais

Téléphone principal : +1 613-786-0222

Courriel : adam.heckman@gowlingwlg.com

Télécharger vCard

Bureau principal :  Ottawa

Connexion au moyen de LinkedIn

Adam Heckman

Adam Heckman is a lawyer and patent agent in Gowling WLG's Ottawa office, and a member of the firm's Intellectual Property Litigation and Life Sciences groups.

Adam primarily practices in the area of patents, trademarks and copyright, with a particular focus on patent litigation. Adam has appeared in the Federal Court and Federal Court of Appeal on behalf of a variety of innovative pharmaceutical and biotechnology companies to enforce and defend their intellectual property rights.

In addition to representing clients in patent infringement and impeachment actions, judicial reviews, and proceedings brought under the Patented Medicines (Notice of Compliance) Regulations, Adam also regularly advises pharmaceutical clients on regulatory matters relating to the Food and Drugs Regulations, patent listing, data protection, certificates of supplementary protection, and issues related to the Patented Medicine Prices Review Board.

Adam was recognized in Best Lawyers: Ones to Watch for work in Intellectual Property Law in 2021 and 2022. He was also counsel for the successful party in one of Managing Intellectual Property (MIP) 2022's "Impact Cases of the Year," before the Federal Court of Appeal.

Prior to joining Gowling WLG, Adam worked as a scientist for an international pharmaceutical development and manufacturing service provider and as a quality assurance associate for an innovative pharmaceutical company.

Adam graduated with a JD from Osgoode Hall Law School, where he won various awards for his academic achievements. He also has a graduate certificate in pharmaceutical regulatory affairs and quality operations, and an honours bachelor of science, specializing in pharmaceutical chemistry.

Mandats représentatifs

  • Counsel to Takeda Pharmaceutical Company at the Federal Court of Appeal, in one of MIP 2022's "Impact Case of the Year," whereby the Court dismissed two appeals brought by Apotex in respect of the validity of certain claims of Takeda's Canadian patent that covers, inter alia, the active ingredient in Takeda's ADHD medication VYVANSE®.
  • Counsel to Eli Lilly and Company and Eli Lilly Canada Inc., the respondents in a dispute with Apotex Inc. before the Federal Court of Appeal, in which the Court affirmed a lower court's decision awarding Eli Lilly $31 million for the infringement of eight Canadian patents for processes involved in the manufacture of cefaclor, an antibiotic used to treat certain bacterial infections; the Court also confirmed that subsection 55(1) of the Patent Act allows for the granting of compound interest as damages and remitted this issue back to the trial judge to provide fuller reasons of his assessment of the evidence on which he further granted Lilly $75 million in damages in the form of interest. - Apotex v. Eli Lilly, 2018 FCA 217
  • Counsel to a pharmaceutical company with respect to the regulatory review of a drug by Health Canada for data protection under the Food and Drug Regulations. After initially denying the request, Health Canada granted an independent term of data protection and a critical period of market exclusivity for at least eight years.

Mandats clients

Mandats représentatifs
11 mars 2021 La Cour d'appel fédérale rejette les appels d'Apotex concernant le brevet canadien VYVANSEMD de Takeda (en anglais)
Mandats représentatifs
29 juin 2018 Défense réussie du brevet canadien VYVANSE® de Shire contre les attaques en invalidation d'Apotex